Pulmonary sarcomatoid carcinoma: University of Cincinnati experience
Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C. Morris · 2017 · Oncotarget
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
// Nagla Abdel Karim 1 , James Schuster 2 , Ihab Eldessouki 1 , Ola Gaber 1 , Tariq Namad 3 , Jiang Wang 4 , Changchun Xie 5 and John C. Morris 1 1 Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, OH 45219, USA 2 University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA 3 Military Hospital of Mohammed V, Department of Medical Oncology, Quartier Irfane, Rabat 10080, Morocco 4 UC Health University Hospital, Department of Pathology and Laboratory Medicine, Cincinnati, OH 45219, USA 5 Division of Biostatistics and Bioinformatics, Department of Environmental H
Abstract by Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C. Morris, Oncotarget (2017) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.18632/oncotarget.23468